Hyderabad, Nov 12 : Covaxin, India’s first indigenous vaccine for Covid-19, has been found to be 77.8 per cent effective, according to the safety and efficacy analysis data from Phase III clinical trials peer reviewed and published in reputed medical journal The Lancet.Hyderabad, November 12, 2012 : .Covaxin has been found to be 77% effective in India.This is according to safety and effectiveness analysis data from Phase III clinical trials, peer-reviewed and published by The Lancet, a reputed medical journal.Hyderabad-based Bharat Biotech said the Lancet peer-review confirms the efficacy analysis which demonstrates Covaxin to be effective against Covid-19.
Bharat Biotech, Hyderabad-based said that the Lancet peer review confirms Covaxin’s efficacy against Covid-19.The vaccine maker Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2 per cent.Covaxin, the vaccine manufacturer for Covid-19 has shown efficacy data in phase III clinical trials against Delta variant 65.2 percent.
A”The efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group,” the company said.The company stated that Covaxin was 77% effective in symptomatic Covid-19.
It has been evaluated in 130 cases and found 24 in the vaccine group, compared to 106 in placebo.
The efficacy analysis also demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19Covaxin is 93.4 percent effective in combating severe symptoms of Covid-19, according to the efficacy analysis.
“Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects experiencing serious adverse events,” it saidIt stated that safety analysis showed adverse events similar to placebo with 12 percent of subjects reporting common side effects, and less than 0.5% of those experiencing severe adverse events.
The efficacy data also shows 63.6 per cent protection against asymptomatic Covid-19, 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta and 70.8 per cent protection against all variants of SARS-CoV-2 virus.Data from the efficacy study also show 63.6 percent protection against symptoms of Covid-19 and 65.2 percentage protection against SARS-CoV-2, Delta, and 70.8 percent protection against all forms of SARS.
Covaxin was developed under a partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology, with Bharat Biotech receiving the SARS-COV-2 strains through this collaboration.Covaxin was created in partnership with Indian Council of Medical Research and National Institute of Virology.
Bharat Biotech received the SARS-COV-2 strains as a result of this collaboration.
Bharat Biotech had established an ongoing collaboration with ViroVax since 2019, through the Indo-US Vaccine Action Program, to develop and evaluate IMDG (Alhydroxiquim-II), a novel TLR7/8 agonist molecule, which is formulated as part of the adjuvant in Covaxin.
Bharat Biotech has been working with ViroVax in an ongoing partnership since 2019.This was through the Indo-US Vaccine Act Program.The goal of this collaboration is to create and assess IMDG (Alhydroxiquim-II), a new TLR7/8 agonist molecule.It’s formulated as part the adjuvant for Covaxin.The Adjuvant Program of the US National Institute of Allergy and Infectious Diseases (NIAID) has supported ViroVax since 2009.Since 2009, ViroVax has been supported by the Adjuvant Program of US National Institute of Allergy and Infectious Diseases.
“The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine validates our commitment to data transparency and meeting the stringent peer-review standards of world leading medical journals,” said Krishna Ella, CMD of Bharat Biotech.Krishna Ella (CMD, Bharat Biotech) stated that the peer review of Covaxin Phase III clinical trial data by The Lancet, an authority in global medicine, validates our commitment data transparency and meeting strict peer-review standard of leading medical journals.”
He said the data from their product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most highly published Covid-19 vaccines in the world.According to him, the Covaxin vaccine is one of the most widely published Covid-19 vaccinations.
The phase 3 trial Efficacy and Safety Study involving 25,800 volunteers across 25 sites in India is India’s largest ever clinical trial conducted for a Covid-19 vaccine.Phase 3 of the Efficacy and Safety Study, which involved 25,800 volunteers at 25 locations in India, was India’s biggest ever clinical trial for a Covid-19 vaccination.
“I am delighted to see that the phase III efficacy data has also been published in The Lancet, one of the most reputed journals worldwide.I am pleased to report that phase III data on efficacy have been published in The Lancet.
This journal is one of the most respected journals around the world.This itself speaks high about the strong position of Covaxin amongst other global front-runners Covid-19 vaccines.
A The bench to bedside journey of Covaxin in less than 10 months showcases the immense strength of Atmanirbhar Bharat along with the Indian academia and industry in fighting against the odds and carving a niche in the global community,” said Balram Bhargava, Director General of the ICMR.This speaks volumes about Covaxin’s strong position among other Covid-19 front-runners.
Balram Bhargava is Director General at the ICMR.
Recently, the World Health Organization granted emergency use listing to Covaxin enabling countries to expedite their regulatory approval to import and administer doses.
The World Health Organization recently granted Covaxin an emergency use listing, allowing countries to quickly obtain regulatory approvals to import or administer dosages.It has also received emergency use authorizations in several countries with applications in process in more than 50 countries worldwide.
The company has received authorizations for emergency use in many countries, with more than 50 applications currently in progress in over 50 countries.Bharat Biotech has partnered with Ocugen to obtain approvals for Covaxin in the US and Canada.
Bharat Biotech has joined forces with Ocugen in order to get approvals for Covaxin within the USA and Canada.
With more than 150 million doses manufactured, supplied, and with an excellent safety and efficacy profile, Covaxin is a major contributor to the global fight against the Covid-19 pandemic.
Covaxin contributes greatly to global efforts against the Covid-19 pandemic.It has been manufactured in excess of 150 million units and is available for supply.
The vaccine is currently being evaluated in controlled clinical trials in children 2-18 years of age, with results expected during Q4 2021.The vaccine is being tested in clinical trials with children aged 2-18 years.
Results are expected in Q4 2021.
Bharat Biotech said it was poised to achieve its goal of an annualized capacity of Aabout 1 billion doses of Covaxin by the end of 2021.
Bharat Biotech stated that it is on track to reach its annualized production capacity of approximately 1 billion Covaxin doses by 2021 #published #Lancet #Covaxin #effective #Hyderabad
.
